Purple Biotech Ltd ADR (PPBT)

$0.59 +0.01 (2.20%)
Market Cap 7.42M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 230,000
Avg Vol 1,295,172
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 28%
Beta 0.61
Analysts Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
bigstocks307
bigstocks307 Oct. 25 at 4:09 PM
$PPBT https://www.sciencedaily.com/releases/2025/10/251018102122.htm
0 · Reply
Stocksavior14
Stocksavior14 Oct. 25 at 3:52 PM
$PPBT yep. Another RS is coming. I hope the bulls stay…. ZERO OR HERO right? LOL plus it’s probably the most bullish it’s ever been heading towards a 3rd reverse split in their insane heads. Eventually they will be left with 1 share worth $4.20 LOL
0 · Reply
FBP
FBP Oct. 25 at 3:30 PM
$PPBT in a market bubble, speculation runs wild. 35%+ of nasdaq stocks are at ATHs with zero revenue. A record since 2000 bubble. This is not one of them. If a stock like this can’t thrive in an either 2021 clown market or this bubble, it is destined to continue its path to zero. See ya next r/s
1 · Reply
LetItRip675
LetItRip675 Oct. 24 at 4:30 PM
$PPBT I need a cigarette
1 · Reply
dogood
dogood Oct. 24 at 4:28 PM
$ADIL all of three of them should fly double digits , shorts should have concern and close it asap $ADIL $PPBT $TOVX - all three of them expecting 2 digits without reverse split
3 · Reply
Stocksavior14
Stocksavior14 Oct. 24 at 4:27 PM
$PPBT the next reverse split will mean that the long time bulls would have had their shares divided by 2000+ 🤣🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Oct. 24 at 4:25 AM
$PPBT they are waiting until after the next reverse split so that they can rinse and repeat
0 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 11:22 PM
$PPBT yup 👇👇
0 · Reply
Smittysixty
Smittysixty Oct. 23 at 8:04 PM
$PPBT The FUD is getting insanely lazy. The ole line: “It hasn’t happened yet, so it never will.” That’s the same script used on every small-cap biotech before an acquisition or breakout. Do they really think retail hasn’t seen this chart pattern before? Do they really think we can’t recognize the setup? We’ve watched this movie: 📉 Suppressed chart 🤫 Strategic silence 📈 Catalyst unlock → acquisition or deal At this point, they aren’t debating — they’re just posting noise to bury legitimate DD. And the louder they get, the more obvious the setup becomes. Lazy FUD can’t erase facts.
0 · Reply
Smittysixty
Smittysixty Oct. 23 at 8:00 PM
$PPBT Institutions don’t step into a private placement at the lows for fun. • Intracoastal + Orca Capital + Lincoln Strategies: new positions in September • NT‑219 100mg data still unreleased • CM‑24 Phase 2b trial ready to launch • IP locked in major markets • BIO-Europe + ESMO IO = global partnering windows Bottom line: Institutions don’t buy lottery tickets. They buy setups.
0 · Reply
Latest News on PPBT
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 20, 2025, 4:00 PM EDT - 5 days ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 7 weeks ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 3 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 4 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 5 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 5 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 6 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 8 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 8 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 11 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 11 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 11 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 15, 2022, 7:00 AM EST - 3 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

bigstocks307
bigstocks307 Oct. 25 at 4:09 PM
$PPBT https://www.sciencedaily.com/releases/2025/10/251018102122.htm
0 · Reply
Stocksavior14
Stocksavior14 Oct. 25 at 3:52 PM
$PPBT yep. Another RS is coming. I hope the bulls stay…. ZERO OR HERO right? LOL plus it’s probably the most bullish it’s ever been heading towards a 3rd reverse split in their insane heads. Eventually they will be left with 1 share worth $4.20 LOL
0 · Reply
FBP
FBP Oct. 25 at 3:30 PM
$PPBT in a market bubble, speculation runs wild. 35%+ of nasdaq stocks are at ATHs with zero revenue. A record since 2000 bubble. This is not one of them. If a stock like this can’t thrive in an either 2021 clown market or this bubble, it is destined to continue its path to zero. See ya next r/s
1 · Reply
LetItRip675
LetItRip675 Oct. 24 at 4:30 PM
$PPBT I need a cigarette
1 · Reply
dogood
dogood Oct. 24 at 4:28 PM
$ADIL all of three of them should fly double digits , shorts should have concern and close it asap $ADIL $PPBT $TOVX - all three of them expecting 2 digits without reverse split
3 · Reply
Stocksavior14
Stocksavior14 Oct. 24 at 4:27 PM
$PPBT the next reverse split will mean that the long time bulls would have had their shares divided by 2000+ 🤣🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Oct. 24 at 4:25 AM
$PPBT they are waiting until after the next reverse split so that they can rinse and repeat
0 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 11:22 PM
$PPBT yup 👇👇
0 · Reply
Smittysixty
Smittysixty Oct. 23 at 8:04 PM
$PPBT The FUD is getting insanely lazy. The ole line: “It hasn’t happened yet, so it never will.” That’s the same script used on every small-cap biotech before an acquisition or breakout. Do they really think retail hasn’t seen this chart pattern before? Do they really think we can’t recognize the setup? We’ve watched this movie: 📉 Suppressed chart 🤫 Strategic silence 📈 Catalyst unlock → acquisition or deal At this point, they aren’t debating — they’re just posting noise to bury legitimate DD. And the louder they get, the more obvious the setup becomes. Lazy FUD can’t erase facts.
0 · Reply
Smittysixty
Smittysixty Oct. 23 at 8:00 PM
$PPBT Institutions don’t step into a private placement at the lows for fun. • Intracoastal + Orca Capital + Lincoln Strategies: new positions in September • NT‑219 100mg data still unreleased • CM‑24 Phase 2b trial ready to launch • IP locked in major markets • BIO-Europe + ESMO IO = global partnering windows Bottom line: Institutions don’t buy lottery tickets. They buy setups.
0 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 6:58 PM
$PPBT somebody better tell Kingswood that smart money is buying here… at least that is what @Smittysixty is saying. #lostanotherone
0 · Reply
revueltoL
revueltoL Oct. 23 at 5:57 PM
$PPBT it needs direction from here, so give it one…you already know which way you plan to take it, so why wait? 😀
1 · Reply
Stocksavior14
Stocksavior14 Oct. 23 at 4:54 PM
$PPBT lol the permabulls are eyeing the next reverse split and have never been more bullish🤦🏼‍♂️🤦🏼‍♂️🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Oct. 23 at 4:54 PM
$PPBT is hadn’t in over 4 years. Doubt it’s changing now LOL
0 · Reply
GoGetYourShineBox
GoGetYourShineBox Oct. 23 at 4:29 PM
$PPBT
0 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 2:07 PM
$PPBT I find it amusing that if something doesn’t fit the narrative, it is dismissed as lazy. Yet posting the same, tired, BS over and over is some kind of deep DD. The same BS that never comes to fruition.
0 · Reply
Purplepayday
Purplepayday Oct. 23 at 1:21 PM
$PPBT it looks like we have a golden cross on the chart today…. Let’s see if that brings anything of interest 🤷🏻‍♂️
1 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 1:19 PM
$PPBT Yael probably just closing the deal from Bio-Europe 2023, right @Smittysixty? this time will be different 🤡
0 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 12:59 PM
$PPBT Dude attended one Tire-Europe convention and thinks he is some sort of expert. Been over 5 years since our “2020 collaboration”, yet this is the strategic plan… what a joke.
1 · Reply
Smittysixty
Smittysixty Oct. 23 at 12:41 PM
$PPBT Lazy FUD alert: “No CEO, no deal.” That’s not how BIO-Europe works. BIO-Europe isn’t a press tour — it’s a partnering engine. Over 30,000 one-on-one meetings, 5,700+ attendees, and top pharma scouts on site. Deals don’t happen on stage — they happen in private rooms. Purple’s sending its Director of Business Development — the one who actually initiates partnerships. She’s armed with: • 🧬 NT‑219 100mg data (unreleased) • 🧪 CM‑24 Phase 2b trial (ready to launch) • 💼 M&A-focused CFO + board stacked with dealmakers • 🔒 Global IP + diversified pipeline • 💰 Extended runway to mid- This isn’t a boondoggle. It’s a negotiation. And the louder the trolls get, the closer we are to a deal.
1 · Reply
PPBTPhoenix
PPBTPhoenix Oct. 23 at 12:37 PM
$PPBT BIO-Europe is a meet and greet. Purple is not presenting. Not sending CEO. Not sending CBO. Not sending CMO. Not sending decision maker. Begging for meetings on a LinkedIn post will not get a deal done. I hope she enjoys the massage lounge and bubbly reception. #boondoggle
2 · Reply
vinland
vinland Oct. 23 at 12:15 PM
$PPBT Old habit but since I'm still here i had to look at latest patent stuff. We may be close, or not, to getting another EU patent granted for 219, this for the anti PD-1 combinations. Last month the reviewer said this app is likely to proceed to grant once a few of their objections are overcome. I think this app expires around 2037, times a ticking.
0 · Reply